Evidence map›Paper›PMID 41578072›Full record

ArticleInternational journal of clinical oncology2026

Reassessing prognostic markers in metastatic renal cell carcinoma in the era of immune checkpoint inhibitors: the enduring value of body composition, nutritional, and inflammatory indices.

Norihiko Tsuchiya, Sei Naito, Hiroki Fukuhara, Hayato Nishida, Mayu Yagi, Yuki Takai, Atsushi Yamagishi, Takafumi Narisawa, Shinta Suenaga

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in International journal of clinical oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Norihiko TsuchiyaFaculty of Medicine, Department of Urology, Yamagata University, 2-2-2 Iida-Nishi, Yamagata, 990-9585, Japan. ntsuchiya@med.id.yamagata-u.ac.jp.ORCID http://orcid.org/0000-0003-4242-2618
Sei NaitoFaculty of Medicine, Department of Urology, Yamagata University, 2-2-2 Iida-Nishi, Yamagata, 990-9585, Japan.
Hiroki FukuharaFaculty of Medicine, Department of Urology, Yamagata University, 2-2-2 Iida-Nishi, Yamagata, 990-9585, Japan.
Hayato NishidaFaculty of Medicine, Department of Urology, Yamagata University, 2-2-2 Iida-Nishi, Yamagata, 990-9585, Japan.
Mayu YagiFaculty of Medicine, Department of Urology, Yamagata University, 2-2-2 Iida-Nishi, Yamagata, 990-9585, Japan.
Yuki TakaiFaculty of Medicine, Department of Urology, Yamagata University, 2-2-2 Iida-Nishi, Yamagata, 990-9585, Japan.
Atsushi YamagishiFaculty of Medicine, Department of Urology, Yamagata University, 2-2-2 Iida-Nishi, Yamagata, 990-9585, Japan.
Takafumi NarisawaFaculty of Medicine, Department of Urology, Yamagata University, 2-2-2 Iida-Nishi, Yamagata, 990-9585, Japan.
Shinta SuenagaFaculty of Medicine, Department of Urology, Yamagata University, 2-2-2 Iida-Nishi, Yamagata, 990-9585, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundImmune checkpoint inhibitors (ICIs) are now the standard first-line treatment for metastatic renal cell carcinoma (mRCC), yet many risk factors identified during the tyrosine kinase inhibitor era remain unvalidated in current practice. This study aimed to evaluate the prognostic value of body composition, nutritional, and inflammatory indices in the era of ICI-based first-line therapy.

methodsWe retrospectively analyzed 136 mRCC patients who received systemic therapy. Body composition indices (skeletal muscle index [SMI], visceral adipose tissue index [VATI], subcutaneous adipose tissue index [SATI]), nutritional markers (prognostic nutritional index [PNI], geriatric nutritional risk index [GNRI]), and inflammatory markers (Glasgow Prognostic Score [GPS], systemic inflammatory index [SII], and other indices) were assessed for their association with overall survival (OS). We also compared their prognostic impact on patients treated with non-ICI-based and ICI-based regimens as first-line therapy.

resultsLow VATI (HR 1.64, P = 0.030), and low SATI (HR 2.22, P < 0.001) were associated with shorter survival. PNI (HR 1.70, P < 0.001) and GNRI (HR 1.57, P < 0.001) showed strong prognostic value, as did GPS (HR 2.43, P < 0.001) and SII (HR 2.11, P < 0.001) in the overall cohort. In the ICI-based regimen group, PNI, GNRI, and SATI demonstrated higher prognostic performance (C-indices 0.736, 0.730, and 0.690, respectively), with PNI and SATI providing clear OS stratification.

conclusionSeveral indices reflecting body composition, nutritional status, and systemic inflammation remain valuable prognostic markers in patients with mRCC receiving ICI-based first-line therapy.

Indexed as

Body CompositionCarcinoma, Renal CellImmune Checkpoint InhibitorsKidney NeoplasmsAgedAged, 80 and overBiomarkers, TumorFemaleHumansInflammationMaleMiddle AgedNutritional StatusNutrition AssessmentPrognosisRetrospective StudiesBiomarkers, TumorImmune Checkpoint InhibitorsBody compositionImmune checkpoint inhibitorMetastatic renal cell carcinomaNutritional statusSystemic inflammation

Identifiers

PMID41578072
PMCPMC12932366

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.